Latest news
Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of…
Debiopharm Group invests in Searchbox SA, a semantic search engine for professionals
The Japanese Cancer Association and Debiopharm Group present the JCA-Mauvernay Award to Dr Ushijima for his oncology research
BioAlps annonce le lauréat de son prix : la famille Mauvernay, fondatrice de Debiopharm, une famille d’entrepreneurs au service de…
Ipsen and Debiopharm conclude an exclusive worldwide license agreement for the development and commercialisation of the Ipsen’s proprietary CDC25 inhibitor…
The Debiopharm Life Sciences Award goes to Dr Lluis Quintana-Murci for his novel and original research on the human evolutionary…
Debiopharm Group and Mercury Therapeutics, Inc. sign an exclusive license agreement for the development and commercialisation of Debio 0930 –…
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
Debiopharm and MSM Protein Technologies sign agreement for Research and Development of Debio 0929, a Novel Oncology Biologic